Public may refuse pandemic vaccine over safety concerns

21 August 2009

Parents and health care workers may refuse to get immunized or vaccinate their children against a pandemic virus if they believe the risks of a novel vaccine outweigh the benefits, according to research published in Emerging Health Threats Journal ( http://dx/doi.org/10.1034/ehtj.09.008).

As the influenza A(H1N1) pandemic threatens to pick up speed as winter approaches in the northern hemisphere, pharmaceutical companies are racing to produce a vaccine against the novel 'swine flu' virus. The first batches of vaccine could be used to protect vulnerable populations as well as to ensure the pandemic does not compromise health care availability. But immunisation in communities is most effective when enough people are vaccinated to confer 'herd immunity' on the rest of the population. Members of the public who refuse the jab for themselves or their children could compromise this wider protective effect, the researchers say.

The researchers, Natalie Henrich of the University of British Columbia and Bev Holmes at Simon Fraser University, Vancouver, Canada, conducted eleven focus groups in Vancouver before the onset of the current pandemic, and asked participants how willing they would be to accept a new vaccine in the event of a pandemic.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical